Mithridion, Inc.
http://mithridion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mithridion, Inc.
ADDF Leaders Discuss Future Strategies In Alzheimer’s Research And Crucial Role Of Diagnostic Markers
Medtech Insight talked to two leaders at the Alzheimer’s Drug Discovery Foundation about current therapies and the role of biomarkers and digital tools to build on recent advancements in the space and accelerate progress to identify the disease early and slow cognitive decline.
Recent Financings of Private Companies (02/2011)
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
Mithridion raises new funds for its CNS focus, and seeks partners
Mithridion Inc, a drug development company in Madison, Wisconsin focusing on serious central nervous system disorders such as Alzheimer's disease and schizophrenia, has announced that it has secured $1.25 million in new funding, and that it is seeking partners for its lead drug candidates.
AC Immune SA
Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice